Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: A pilot study in humans

Gene Therapy

Volumn 6, Issue 3, 1999, Pages 330-337

  Palu G ^b   Cavaggioni, A ^c   Calvi, P ^c   Franchin, E ^c   Pizzato, M ^c   Boschetto, R ^c   Parolin, C ^c   Chilosi, M ^c   Ferrini, S ^a   Zanusso, A ^c   Colombo, F ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c NONE

Author keywords

Brain tumours; Gene therapy; Glioblastoma multiforme; Interleukin 2; Retroviral bicistronic vector; Thymidine kinase

Indexed keywords

CYTOKINE; INTERLEUKIN 2; THYMIDINE KINASE;

ADULT; ARTICLE; CASE REPORT; GENE EXPRESSION; GENE THERAPY; GLIOBLASTOMA; HUMAN; IMMUNOMODULATION; PRIORITY JOURNAL; PROGNOSIS; RETROVIRUS; SUICIDE GENE; TRANSGENE; TUMOR GROWTH;

ADULT; BRAIN; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; INTERLEUKIN-2; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PILOT PROJECTS; RETROVIRIDAE; THYMIDINE KINASE; TRANSFECTION;

EID: 0033000339     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300805     Document Type: Article

References (28)

1. Oldfield EH et al. Clinical protocol: gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993; 4: 39-69.
2. Elshami AA et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Therapy 1996; 3: 85-92.
3. Hamel W et al. Herpes simplex virus thymidine kinase/ ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 1996; 56: 2697-2701.
4. Long Z et al. Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells. Hum Gene Ther 1998; 9: 1165-1172.
5. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: McLeod CM (ed). Evaluation of Chemotherapeutic Agents. Columbia University Press: New York, 1945, pp 191-205.
6. Chilosi M et al. Multimarker immunohistochemical staining of calgranulins, chloroacetate esterase, and S100 for simultaneous demonstration of inflammatory cells on paraffin sections. J Histochem Cytochem 1990; 38: 1669-1675.
7. Vile RG et al. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 1997; 71: 267-274.
8. Pizzato M et al. Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer. Gene Therapy 1998; 5: 1003-1007.
9. Barba D et al. Intratumoral LAK cell and interleukin 2 therapy of human gliomas. J Neurosurg 1989; 70: 175-182.
10. O'Reilly MS et al. Endostatin: an endogenous inhibitor of angiogenesis and rumor growth. Cell 1997; 88: 277-285.
11. Bi WL et al. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
12. Ram Z et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med 1997; 3: 1354-1361.
13. Tjuvajev J et al. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res 1995; 55: 1902-1910.
14. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
15. Hamel W, Magnelli L, Chiarugi VP, Isreal MA. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 1996; 56: 2697-2702.
16. Freeman SM et al. The role of cytokines in mediating the bystander effect using HSV-tk xenogeneic cells. Cancer Lett 1995; 92: 167-174.
17. Gagandeep S et al. Prodrug-activated gene therapy: involvement of an immunological component in the 'bystander effect'. Cancer Gene Ther 1996; 3: 83-88.
18. Yamamoto S et al. Herpes simplex virus thymidine kinase/ ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice. Cancer Gene Ther 1997; 4: 91-96.
19. Meazza R et al. Analysis of IL-2 receptor expression and of the biological effects of IL-2 gene transfection in small-cell lung cancer. Br J Cancer 1996; 74: 788-795.
20. Riddell SR et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med 1996; 2: 216-223.
21. Colombo MP, Forni G. Immunotherapy 1: cyclosine gene transfer strategies. Cancer Metastasis Rev 1996; 15: 317-328.
22. Corrias MV et al. Characterization and tumorigenicity of human neuroblastoma cells transfected with the IL-2 gene. Cancer Gene Ther 1998; 5: 38-44.
23. Cosset FL et al. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430-7436.
24. Ram Z et al. Summary of results and conclusions of the gene therapy of malignant brain tumors: clinical study. J Neurosurg 1995; 82: 343A.
25. Rho HM et al. Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology 1981; 112: 355-360.
26. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
27. Schaeren-Wiemers N, Gerfin-Moser A. A single protocol to detect transcripts of various types and expression levels in neural tissue and cultured cells: in situ hybridization using digoxigenin-labelled cRNA probes. Histochemistry 1993; 100: 431-440.
28. Chilosi M et al. p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function. Blood 1996; 88: 4012-4020.